

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 February 2019 (14.02.2019)



(10) International Publication Number
WO 2019/032675 A1

(51) International Patent Classification:

C12N 5/0783 (2010.01) C12N 15/113 (2010.01)
C12N 15/90 (2006.01) A61K 35/17 (2015.01)

(21) International Application Number:

PCT/US2018/045759

(22) International Filing Date:

08 August 2018 (08.08.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/542,511	08 August 2017 (08.08.2017)	US
62/581,290	03 November 2017 (03.11.2017)	US
62/613,258	03 January 2018 (03.01.2018)	US
62/652,672	04 April 2018 (04.04.2018)	US

(71) Applicant: **SANGAMO THERAPEUTICS, INC.**
[US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(72) Inventors: **CONWAY, Anthony**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **JAIN, Sumiti**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **LEE, Gary K.**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **REIK, Andreas**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **TRUONG, Lynn N.**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(74) Agent: **PASTERNAK, Dahna**; PASTERNAK PATENT LAW, 1900 Embarcadero Rd., Suite 211, Palo Alto, California 94303 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

(54) Title: CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING




FIG. 7

(57) Abstract: Disclosed herein are methods and compositions for engineering cells to express a CAR where the cells also have inactivated TCR, HPRT, PD1, CISH and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.

[Continued on next page]



WO 2019/032675 A1

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))